tiprankstipranks
Xencor Inc. (CH:XE9)
NASDAQ:XE9
Switzerland Market
XE9
Xencor
RESEARCH TOOLSreports

Xencor (XE9) Earnings Dates, Call Summary & Reports

0 Followers

Earnings Data

Report Date
Aug 05, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.65
Last Year’s EPS
-0.33
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 11 Analysts Ratings

Earnings Call Summary

Q4 2023
Earnings Call Date:Feb 27, 2024|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant pipeline progress and a strong financial position. However, safety concerns with vudalimab and a strategic pause on XmAb564 development were noted.
Company Guidance
During Xencor's fourth-quarter 2023 earnings call, the company provided comprehensive guidance on its clinical pipeline and financial outlook. They highlighted a significant focus on the development of bispecific T-cell engagers for solid tumors, including XmAb819 and XmAb808, with ongoing Phase I studies in renal cell carcinoma and prostate cancer, respectively. Vudalimab, a key candidate, showed promising monotherapy results in heavily pre-treated metastatic castrate-resistant prostate cancer patients, with a RECIST response rate of 35% and a PSA90 rate of 25%. Financially, Xencor bolstered its balance sheet through the partial monetization of Ultomiris and Monjuvi royalties, ending 2023 with $697 million, ensuring operational runway until 2027. The company's 2024 priorities include advancing its solid tumor bispecific programs and selecting the next IND candidate, while maintaining a strategic focus on T-cell engager discovery and development.
Strong Financial Position
Xencor ended 2023 with $697 million, providing runway into 2027 due to robust milestone and royalty revenues.
Clinical Pipeline Progress
Significant advancement in bispecific T-cell engagers for solid tumors, including vudalimab in prostate and lung cancer.
Encouraging Vudalimab Data
The prostate cancer monotherapy cohort showed a RECIST response rate of 35% and a disease control rate of 50%.
XmAb Bispecific Technology Development
XmAb bispecific technology shows promise for solid tumor selectivity, with ongoing studies in renal and prostate cancer.

Xencor (CH:XE9) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

CH:XE9 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2026
2026 (Q2)
-0.65 / -
-0.332―――
May 06, 2026
2026 (Q1)
-0.67 / -1.38
-0.535-159.09% (-0.85)――
Feb 25, 2026
2025 (Q4)
-0.49 / -0.07
-0.50285.48% (+0.43)――
Nov 05, 2025
2025 (Q3)
-0.56 / -0.06
-0.57588.73% (+0.51)――
Aug 06, 2025
2025 (Q2)
-0.58 / -0.33
-0.86761.68% (+0.53)――
May 07, 2025
2025 (Q1)
-0.47 / -0.53
-0.89940.54% (+0.36)――
Feb 27, 2025
2024 (Q4)
-0.63 / -0.50
-0.251-100.00% (-0.25)――
Nov 07, 2024
2024 (Q3)
-0.79 / -0.58
-0.324-77.50% (-0.25)――
Aug 05, 2024
2024 (Q2)
-0.67 / -0.87
-0.3-189.19% (-0.57)――
May 09, 2024
2024 (Q1)
-0.67 / -0.90
-0.826-8.82% (-0.07)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

FAQ

When does Xencor Inc. (CH:XE9) report earnings?
Xencor Inc. (CH:XE9) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
    What is Xencor Inc. (CH:XE9) earnings time?
    Xencor Inc. (CH:XE9) earnings time is at Aug 05, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Xencor Inc. stock?
          The P/E ratio of Xencor is N/A.
            What is CH:XE9 EPS forecast?
            CH:XE9 EPS forecast for the fiscal quarter 2026 (Q2) is -0.65.